

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop: S2-01-16
Baltimore, Maryland 21244-1850



Children and Adults Health Programs Group

June 25, 2014

Ruth Kennedy
Medicaid Director
State of Louisiana Department of Health and Hospitals
628 North 4th Street
Baton Rouge, LA 70802

Dear Ms. Kennedy:

Thank you for the state's communication regarding the extension of Louisiana's Take Charge Family Planning 1115 demonstration (Project No. 11-W-00232/6). The state's family planning services state plan amendment (SPA) will be implemented on July 1, 2014 and will provide coverage for family planning services for individuals up to and including 133 percent of the federal poverty level (FPL). Women with higher income levels have been receiving coverage for family planning services for this demonstration, which is due to expire on June 30, 2014. The state requested an extension of the demonstration through December 31, 2014 for individuals between 134 percent through 200 percent of the FPL.

With this letter, the Centers for Medicare & Medicaid Services (CMS) is granting a temporary extension of your program until December 31, 2014. This temporary extension will allow the state to continue providing family planning services to women who have household incomes above 133 percent of the FPL until the earliest date that such women could obtain health coverage purchased on the Federally-Facilitated Marketplace (FFM) by applying during the next open enrollment period.

The demonstration is currently operating under the authority of section 1115(a) of the Social Security Act. The current list of expenditure authorities and special terms and conditions will continue to apply during the temporary extension of the Take Charge Family Planning demonstration until December 31, 2014.

We look forward to continuing to work with you and your staff on this demonstration.

Sincerely,

/s/

Eliot Fishman
Director

cc: Bill Brooks, Associate Regional Administrator, Region VI
Ford Blunt, Dallas Regional Office

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop: S2-01-16
Baltimore, Maryland 21244-1850



Children and Adults Health Programs Group

February 28, 2014

Ruth Kennedy
Medicaid Director
State of Louisiana Department of Health and Hospitals
628 North 4th Street
Baton Rouge, LA 70802

Dear Ms. Kennedy:

Thank you for the state's communication regarding the extension of Louisiana's Take Charge Family Planning (Project No. 11-W-00232/6) 1115 demonstration. The state requested that the current program, which is due to expire on March 31, 2014, be extended to June 30, 2014.

With this letter, the Centers for Medicare & Medicaid Services (CMS) is granting a temporary extension of your program until June 30, 2014. The demonstration is currently operating under the authority of section 1115(a) of the Social Security Act. Additionally, the current list of expenditure authorities and special terms and conditions will continue to apply to the Take Charge Family Planning demonstration until June 30, 2014.

We look forward to continuing to work with you and your staff on this demonstration.

Sincerely,

/s/

Eliot Fishman
Director

cc: Bill Brooks, Associate Regional Administrator, Region VI
Ford Blunt, Dallas Regional Office

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-01-16
Baltimore, Maryland 21244-1850



Children and Adults Health Programs Group

June 27, 2013

Ruth Kennedy
Medicaid Director
State of Louisiana Department of Health and Hospitals
628 North 4th Street
Baton Rouge, LA 70802

Dear Ms. Kennedy:

With this letter, the Centers for Medicare & Medicaid Services (CMS) is granting a temporary extension of Louisiana's Take Charge Family Planning (Project No. 11-W-00232/6) demonstration until March 31, 2014. The demonstration is currently operating under the authority of section 1115(a) of the Social Security Act. The current lists of waiver and expenditure authorities and special terms and conditions will continue to apply to the Take Charge Family Planning demonstration until March 31, 2014. We continue to process your extension request and look forward to continuing to work with your staff on the request.

As you know, starting January 1, 2014, eligibility for Medicaid for most individuals will be determined using methodologies that are based on modified adjusted gross income (MAGI). This requirement applies to eligibility for family planning section 1115 demonstrations. In addition, starting October 1, 2013, states are also required to make available a single, streamlined application for MAGI-based eligibility.

We understand that there are special attributes of this demonstration to consider when deciding how to integrate family planning eligibility into the state's MAGI eligibility rules and the single, streamlined application process. Should you need additional time to integrate these features into your family planning section 1115 demonstration, CMS requests that you use the standard process of requesting acceptable mitigations.

Your project officer, Shanna Wiley, with the Division of State Demonstrations and Waivers, is available to work with you to determine the appropriate approach for your state if you are not able to integrate these features into your family planning 1115 demonstration by January 1, 2014. Please do hesitate to contact Ms. Wiley at (410) 786-1370, or at shanna.wiley@cms.hhs.gov.

Sincerely,

/s/

Jennifer Ryan
Acting Director

cc: Bill Brooks, ARA, Region VI
Ford Blunt, Dallas Regional Office



JUN - 6 2006

Mr. Jerry Phillips
Acting Director
Louisiana Department of Health and Hospitals
Office of Management & Finance
Bureau of Health Services Financing
1201 Capitol Access Road
P.O. Box 91030
Baton Rouge, LA 70821-9030

Dear Mr. Phillips:

We are pleased to inform you that Louisiana's request for its Section 1115 Family Planning Demonstration, as modified by the Special Terms and Conditions (STCs) accompanying this award letter, has been approved as project number 11-W-00232/6. Under this demonstration, the State will cover family planning services for uninsured women, ages 19 through 44, who are not otherwise eligible for Medicaid, State Children's Health Insurance Program, Medicare, or any other creditable health insurance coverage, and who have family income at or below 200 percent of the Federal poverty level (FPL). Approval for this demonstration is under the authority of section 1115 of the Social Security Act (the Act) and is effective as of the first of the month following this approval for a 5-year period.

Enclosed are the STCs that the State must meet as a condition for approval of this demonstration. These STCs define the nature, character, and extent of Federal involvement in this project. This award letter is subject to our receipt of your written acceptance of the award, including the STCs, within 30 days of the date of this letter.

All requirements of the Medicaid program as expressed in law, regulation, and policy statement not expressly identified as not applicable in this letter, shall apply to the Louisiana family planning Demonstration.

Medicaid Costs Not Otherwise Matchable

Under the authority of section 1115(a)(2) of the Act, the following expenditures that would otherwise not be regarded as expenditures under title XIX of the Act will be regarded as expenditures under the State's title XIX plan. All requirements of the Medicaid statute will be applicable to such expenditure authorities, except those specified below as not applicable to these expenditure authorities. In addition, all requirements in the enclosed STCs will apply to these expenditure authorities.

Expenditures for family planning services for uninsured women, ages 19 through 44, who are not otherwise eligible for Medicaid, SCHIP, Medicare, or any other creditable health insurance coverage, and who have family income at or below 200 percent of the FPL.

Medicaid Requirements Not Applicable to the Medicaid Expenditure Authorities:

All Medicaid requirements apply, except the following:

1. Amount, Duration, and Scope of Services (Comparability)-Section 1902(a)(10)(B)

The State will offer to the demonstration population a benefit package consisting only of approved family planning services.

2. Early and Periodic Screening, Diagnostic, and Treatment (EPSDT)-Section 1902(a)(43)(A)

The State will not furnish or arrange for EPSDT services to the demonstration population.

3. Retroactive Coverage-Section 1902(a)(34)

Individuals enrolled in the family planning demonstration program will not be retroactively eligible.

4. Prospective Payment System for Federally Qualified Health Centers and Rural Health Clinics-Section 1902(a)(15)

To enable the State to establish reimbursement levels to these clinics that would compensate them solely for family planning services.

Your project officer is Ms. Tonya Moore, who may be reached at (410) 786-0019. Ms. Moore is available to answer any questions concerning the scope and implementation of the project in your application. Communications regarding program matters, and official correspondence concerning the project, should be submitted to the project officer at the following address:

Centers for Medicare & Medicaid Services
Center for Medicaid and State Operations
7500 Security Boulevard, Mail Stop: S2-01-16
Baltimore, MD 21244-1850
E-mail: Tonya.Moore@cms.hhs.gov

Official communications regarding program matters should be submitted simultaneously to Ms. Moore and to Mr. Andrew Frederickson, Associate Regional Administrator, in the Dallas Regional Office. Mr. Frederickson's address is:

Centers for Medicare & Medicaid Services
Office of the Regional Administrator
1301 Young Street, Room 714
Dallas, TX 75202

We extend our congratulations to you on this award and look forward to working with you during the course of the demonstration.

Sincerely,

/Mark B. McClellan/
Mark B. McClellan, M.D., Ph.D.

Enclosures

Page:4-Mr.JerryPhillips

cc:
Andrew Fredrickson, ARA, CMS Dallas Regional Office

Centers for Medicare & Medicaid Services (CMS)
Special Terms and Conditions

Project Number: 11-W-00232/6
Project Title: Take Charge (Family Planning Demonstration)
State: State of Louisiana

General Financial Requirements

1. All requirements of the Medicaid program expressed in law not expressly waived or identified as not applicable in the demonstration award letter of which these Special Terms and Conditions (STCs) are part, will apply to the Louisiana Section 1115 Family Planning Demonstration.
 - a. The State must, within the time specified in law, regulation, or policy directive, come into compliance with any changes in Federal law, regulation, or policy that occur after the approval date of this demonstration, unless the provision being changed is explicitly waived under the STCs herein governing the demonstration. This requirement shall apply to all regulation and policy issued by CMS with respect to the Deficit Reduction Act of 2005 (DRA) including, but not limited to, the documentation of citizenship requirements contained in section 1137 of the Social Security Act (the Act).
 - b. To the extent that changes in the enforcement of such laws, regulations, and policy statements would have affected State spending without the demonstration, in ways not explicitly anticipated in this agreement, CMS will incorporate such effects into a modified budget limit for this section 1115 Family Planning Demonstration program. The modified budget limit would be effective upon implementation of the change in Federal law, regulation, or policy statement. If the law, regulation, or policy statement cannot be linked specifically with program components that are or are not affected by the section 1115 Family Planning Demonstration (e.g., laws affecting sources of Medicaid funding and/or all disallowances involving provider taxes or donations), the effect of enforcement on the State's budget limit will be proportional to the size of the section 1115 Family Planning Demonstration in comparison to the State's entire Medicaid program (as measured in aggregate medical assistance payments). In addition, the State will submit its methodology to CMS for complying with the change in law. If the methodology is consistent with Federal law and in accordance with Federal projections of the budgetary effects of the new law in Louisiana, CMS would approve the methodology. Should CMS and the State, working in good faith to ensure State flexibility, fail to develop within 90 days of the implementation of the change in Federal law a methodology to revise the without-demonstration baseline that is consistent with Federal law and in accordance with Federal budgetary projections, a reduction in Federal payments will be made according to the method applied in non-demonstration States.
 - c. The State may submit to CMS a request for an amendment to the section 1115 Family Planning Demonstration to request exemption from changes in law occurring after the approval date of the demonstration. The cost to the Federal Government of such an

amendment must be offset to ensure that total projected expenditures under a modified section 1115 Family Planning Demonstration do not exceed projected expenditures in the absence of the family planning section 1115 Family Planning Demonstration (assuming full compliance with the change in law).

d. Budget Neutrality Monitoring Procedures (See Attachment A).

2. The following financial reporting procedures must be adhered to:

The State will report quarterly expenditure reports using Form CMS-64 to separately report expenditures for those receiving services under the Medicaid program and those participating in the demonstration. CMS will provide Federal financial participation (FFP) only for allowable demonstration expenditures that do not exceed the predefined limits as specified in Attachment A. Demonstration participants include all individuals who obtain one or more covered medical family planning service(s) through the demonstration.

- a. In order to track expenditures under this demonstration, Louisiana will report expenditures through the Medicaid and State Children's Health Insurance Program Budget and Expenditures System (MBES/CBES), following routine CMS-64 reporting instructions outlined in section 2500 of the State Medicaid Manual. All expenditures subject to the budget neutrality cap shall be reported on separate Forms CMS-64.9 Waiver and/or 64.9P Waiver, identified by the demonstration project number assigned by CMS (including the project number extension, which indicates the demonstration year (01. . .05) in which services were rendered or for which capitation payments were made). For monitoring purposes, cost settlements attributable to the expenditures subject to the budget neutrality cap must be reported on line 10B, in lieu of lines 9 or 10C.
- b. The Federal share for demonstration expenditures matched at the State's regular match rate should be reported using column (B) of Form CMS 64.9 Waiver and/or 64.9P Waiver and in column (D) for services eligible for the family planning match rate of 90 percent.
- c. All claims for Louisiana's family planning services provided during the demonstration period (including any cost settlements) must be made within 2 years after the calendar quarter in which the State made the expenditures. During the 2-year period following the conclusion or termination of the demonstration, the State must continue to separately identify demonstration expenditures using the procedures outlined above in order to properly account for these expenditures in determining budget neutrality.
- d. Administrative costs will not be included in budget neutrality; however, the State must separately track and report administrative costs attributable to the demonstration on Form CMS-64.10 Waiver and/or 64.10P Waiver.
- e. The State will provide to CMS, on a yearly basis, the average total Medicaid expenditures for a Medicaid-funded birth. The cost of a birth includes prenatal services and delivery, pregnancy-related services, and services to infants from birth up to age 1. (The services should be limited to the services that are available to women who are eligible for Medicaid because of their pregnancy and their infants.)

- f. The State will submit to CMS, on a yearly basis, the number of actual births that occur to demonstration participants (as noted in 2.a., participants include all individuals who obtain one or more covered medical family planning service(s) through the demonstration).
 - g. The Louisiana Medicaid office must institute a data sharing relationship with the State Agency that performs the calculation of the vital statistics in order to ensure State compliance with the birth data reporting requirements under the demonstration. The State must notify CMS if birth data will not be available within 3 months of the end of each demonstration year.
 - h. The State will assure CMS that no duplicative Federal payments will be made for individuals who are enrolled in the State's regular Medicaid program or any other Federally funded program (i.e., title X or title XXI). The State will not use title XIX funds to pay for individuals enrolled in regular Medicaid or any other Federally funded program who seek services under the section 1115 Family Planning Demonstration, if the State is already covering the costs of services for that individual under any of these other programs.
3. The standard Medicaid funding process will be used during the demonstration. Louisiana must continue to estimate total matchable Medicaid expenditures for the entire program on the quarterly Form CMS-37. The State must provide supplemental schedules that clearly distinguish between matchable demonstration expenditure estimates (by major component) and non-demonstration Medicaid expenditure estimates. CMS will make Federal funds available each quarter based upon the State's estimates, as approved by CMS.

Within 30 days after the end of each quarter, the State must submit the Form CMS-64 quarterly Medicaid expenditure report, showing Medicaid expenditures made in the quarter just ended. CMS will reconcile expenditures reported on the Form CMS-64 with Federal funding previously made available to the State for that quarter, and include the reconciling adjustment in the finalization of the award to the State.

- 4. CMS will provide FFP at the appropriate 50 percent administrative match rate for general administration costs, such as, but not limited to, claims processing, eligibility assistance and determinations, outreach, program development, and program monitoring and reporting.
- 5. The State will certify that State/local monies are used as matching funds for demonstration purposes and will further certify that such funds will not be used as matching funds for any other Federal grant or contract, except as permitted by Federal law.
- 6. FFP for services (including prescriptions) provided to women under the section 1115 Family Planning Demonstration will be available at the following rates and as described in Attachment B:
 - a. For services whose primary purpose is family planning (i.e., contraceptives and sterilizations), FFP will be available at the 90 percent matching rate. Procedure codes for

office visits, laboratory tests, and certain other procedures must carry a diagnosis that specifically identifies them as family planning services.

- b. FFP will not be available for the costs of any services, items or procedures that do not meet the requirements specified above, even if family planning clinics or providers provide them. For example, in the instance of testing for sexually transmitted infections (STI) as part of a family planning visit, the match rate would be 90 percent. The match rate for the subsequent treatment would be the regular Federal Medical Assistance Percentage rate. For testing or treatment not associated with a family planning visit (e.g., those provided at a public STI clinic), no match would be available.

Administrative Reports and Deliverables

7. The State will submit narrative progress reports 30 days following the end of each demonstration quarter. The fourth quarterly report of every demonstration year will summarize the preceding demonstration year's activity and serve as the annual report. The format for these reports will be decided upon by CMS and the State. The annual report will be due 90 days following the end of the fourth quarter of each project year. CMS reserves the right to request the annual report in draft for prior review.
8. The State will report to CMS, on a quarterly basis, the number of individuals enrolled in the demonstration at that point in time, as well as the number receiving services during the quarter. This information should be included in the quarterly narrative progress report provided to CMS.
9. Within 30 days from the date of approval of the demonstration, the State shall demonstrate to CMS how enrollees potentially eligible for Medicaid or SCHIP are notified that they may be eligible (for Medicaid or SCHIP) so that these enrollees make an informed decision to enroll in the family planning demonstration instead of the State's Medicaid or SCHIP program.
10. Within 60 days from the date of approval of the demonstration, the State will provide to CMS for approval an appropriate methodology for ensuring the integrity of initial and annual eligibility re-determination of individuals covered under the section 1115 Family Planning Demonstration based on income at or below 200 percent of the Federal poverty level. This methodology will include a description of periodic sampling to ensure the integrity of all self-reported information, including income.
11. Within 60 days from the date of approval of the demonstration, the State will provide to CMS an evaluation plan for approval that ensures the integrity of eligibility determinations, to be conducted on an annual basis. This evaluation plan will include an eligibility determination error rate methodology with a corrective action plan.
12. The State will provide to CMS an updated list of current procedural terminology and HCPCS codes covered under the demonstration on January 31st of each demonstration year. This revised code list should reflect only changes due to updates in these codes and should only include codes for which the State has already received approval.

13. No later than 180 days prior to the end of the demonstration award period, Louisiana shall submit a draft final report to the CMS project officer for comments. The final report will incorporate all CMS comments and evaluation findings. The final report shall also contain a disclaimer that the opinions expressed are those of the State and do not necessarily reflect the opinions of CMS. The final report is due 90 days after the end of the demonstration award period. The final demonstration report may not be released or published without permission from the CMS project officer, except as required by law, within the first 4 months following receipt of the report by the CMS project officer.
14. Louisiana will notify the CMS project officer before formal presentation of any report or statistical or analytical material based on information obtained through this cooperative agreement. Formal presentation includes papers, articles, professional publications, speeches, and testimony. During this research, whenever the State or its designee determines that a significant new finding has been developed, he/she will immediately communicate it to the CMS project officer before formal dissemination to the general public.
15. The State will assume responsibility for the accuracy and completeness of the information contained in all technical documents and reports submitted. The CMS project officer will not direct the interpretation of the data in preparing these documents and reports.
16. At any phase of the demonstration, including the demonstration's conclusion, the State, if so requested by the project officer, must submit to CMS analytic data file(s), with appropriate documentation, representing the data developed/used in end-product analyses generated under the demonstration. The analytic file(s) may include primary data collected or generated under the demonstration and/or data furnished by CMS. The content, format, documentation, and schedule for production of the data file(s) will be agreed upon by the State or its designee and the CMS project officer. The negotiated format(s) could include both the file(s) that would be limited to CMS internal use and the file(s) that CMS could make available to the general public.
17. At any phase of the demonstration, including the demonstration's conclusion, the State, if so requested by the project officer, must deliver any materials, systems, or other items developed, refined, or enhanced during or under the demonstration to CMS. The State agrees that CMS will have royalty-free, nonexclusive, and irrevocable rights to reproduce, publish, or otherwise use and authorize others to use such materials, systems, or items for Federal Government purposes.
18. A phase-out plan for the demonstration needs to be submitted to CMS for approval within 90 days of the award of the demonstration. The phase-out plan must address the fact that the State is responsible for informing enrollees that the demonstration will end 5 years from the beginning date.
19. The State shall submit a revised and updated implementation schedule to CMS within 30 days from the award of the demonstration. The revised schedule will include the implementation of the evaluation of the demonstration and other requirements described in these STCs.

Eligibility Redeterminations

20. The State will ensure that redeterminations of eligibility for this demonstration are conducted, at a minimum, once every 12 months. The process for eligibility redeterminations shall not be passive in nature, but will require that an action be taken by the section 1115 Family Planning Demonstration recipient. Louisiana may satisfy this requirement by having the recipient sign and return a renewal form to verify the current accuracy of the information previously reported to the State.

Primary Care Referral and Evaluation

21. The State shall facilitate access to primary care services for enrollees in the Medicaid Section 1115 Family Planning Demonstration. The State shall submit to CMS a copy of the written materials that are distributed to the family planning demonstration participants as soon as they are available. The written materials must explain to the participants how they can access primary care services. In addition, the State must evaluate the impact of providing referrals for primary care services as described in the State's demonstration evaluation design.
22. Should CMS conduct an independent evaluation of section 1115 Family Planning Demonstrations the State will cooperate fully with CMS or the independent evaluator selected by CMS, to assess the impact of the Medicaid demonstrations and/or to examine the appropriateness of the averted birth budget neutrality methodology. The State will submit the required data to CMS or its contractor.
23. Family planning expenditures under the Medicaid program have increased in recent years and CMS is interested in monitoring these expenditures. Thus, as part of our overall monitoring of the demonstration, CMS will also be monitoring the rate in expenditure growth for family planning services. This monitoring will be done on a per capita basis, using total expenditures recorded during the first year of the demonstration as a baseline. As a frame of reference we will be comparing the annual rate of growth of actual expenditures with the baseline amount trended forward using Consumer Price Index (CPI) Medical. The comparison of actual per capita expenditures over the life of the demonstration and per capita expenditures trended using CPI Medical will be considered if the State should seek an extension of their family planning demonstration.

In addition, a federally-contracted evaluation will examine the appropriateness of the budget neutrality methodology of these demonstrations by assessing the births that have been averted as a result of the demonstrations, the data sources currently used to assess averted births and budget neutrality, and expenditures overall. Based on the evaluation findings and other information, CMS reserves the right to negotiate a new budget neutrality methodology, if CMS deems appropriate. Such a methodology change could range from a change in data sources used to determine budget neutrality, to a total change in methodology, such as incorporating a per capita cap like the one described above. Any and all changes to the budget will be made in full consultation with the State, including expenditure data used in the methodology.

Suspension/Termination of Demonstration

24. Failure to operate the demonstration as approved and according to Federal and State statutes and regulations will result in withdrawal of approval for the demonstration. The Federal statutes and regulations with which the State must comply in the operation of the demonstration include civil rights statutes and regulations that prohibit discrimination on the basis of race, color, national origin, disability, sex, age, and religion, including Privacy Rules at 45 CFR Parts 160 and 164, title VI of the Civil Rights Act of 1964, section 504 of the Rehabilitation Act of 1973, the Age Discrimination Act of 1975, title II of the Americans with Disabilities Act, and the nondiscrimination provisions of the Omnibus Budget Reconciliation Act of 1980.
25. CMS may suspend or terminate any demonstration in whole, or in part, any time before the date of expiration, whenever it determines that the State has materially failed to comply with the terms of the demonstration. CMS will promptly notify the State in writing of the determination and the reasons for the suspension or termination, with the effective date. The budget neutrality test will be applied from the date of implementation through the date of termination, without adjustment.
26. CMS reserves the right to unilaterally terminate the demonstration and the accompanying Federal matching authority if CMS determines that continuing the demonstration would no longer be in the public interest. If a section 1115 Family Planning Demonstration is terminated by CMS, the State will be liable for cumulative costs under the demonstration that are in excess of the cumulative target expenditures specified in the "Expenditure Review" section of Attachment A for the demonstration year of withdrawal.
27. If after the demonstration approval, CMS and the State cannot reach agreement on any item(s) cited in this document either party has the right to terminate the agreement subject to the termination/phase-out terms outlined above.



Deputy Administrator

Baltimore, MD 21244-1850

AUG 31 2007

Mr. Jerry Phillips, Director
Louisiana Department of Health and Hospitals
Office of Management & Finance
Bureau of Health Services Financing
1201 Capitol Access Road
P.O. Box 91030
Baton Rouge, LA 70821-9030

Dear Mr. Phillips:

We are pleased to inform you that Louisiana's request for an amendment of its section 1115 Family Planning Demonstration, project number 11-W-00232/6, has been approved. Specifically, the State requested to provide additional family planning services and medications for women who are enrolled in the demonstration.

The Secretary of Health and Human Services has the discretionary authority to approve demonstrations that promote the objectives of title XIX of the Social Security Act (the Act). We believe the demonstration, as modified, is likely to promote the objectives of the Louisiana Family Planning Project. Thus, we are granting approval of your request to expand services to include the following services and medication codes for participants in the demonstration under the authority of section 1115 of the Act:

- 1) HPCPS/CPT 71010: Radiologic exam, chest single view
- 2) HCPCS/CPT 71020: Radiologic exam, chest 2 views
- 3) Oxycodone HCL/Acetaminophen (Percocet) (NDC codes Attachment B)
- 4) Propoxyphene/Acetaminophen (Darvocet) (NDC codes Attachment B)

The additional services and pain medications will only be paid when billed with the following Family Planning diagnosis codes:

- S662 Bilateral Endoscopic Destruction or Occlusion
- S6621 Bilateral Endoscopic Ligation and Crushing
- S6622 Bilateral Endoscopic Ligation and Division
- S6629 Other Bilateral Endoscopic Destruction
- S663 Other Bilateral Destruction or Occlusion
- S6631 Other Bilateral Ligation and Crushing
- S6639 Other Bilateral Destruction or Occlusion
- V252 Sterilization

Page 2 – Mr. Jerry Phillips

The enclosed Attachment B of the Special Terms and Conditions has been revised to capture the additional services and medications and the conditions under which they will be reimbursed. The approval date of this letter is the effective date of this amendment through the duration of the demonstration.

All requirements of the Medicaid program as expressed in law, regulation, and policy statement not expressly identified as not applicable in this letter, shall apply to the Louisiana Family Planning Demonstration.

Your project officer is Ms. Andrea Casart. She is available to answer any questions concerning modification of your section 1115 Family Planning Demonstration. Ms. Casart's contact information is as follows:

Centers for Medicare & Medicaid Services
Center for Medicaid and State Operations
7500 Security Boulevard, Mail Stop: S2-01-16
Baltimore, MD 21244-1850
Telephone: (410) 786-0742
Facsimile: (410) 786-3517
E-mail: andrea.casart@cms.hhs.gov

Official communications regarding program matters should be submitted simultaneously to Ms. Casart and to Mr. Bill Brooks, Acting Associate Regional Administrator, in the Dallas Regional Office. Mr. Brooks' address is:

Centers for Medicare & Medicaid Services
Office of the Regional Administrator
1301 Young Street, Room 833
Dallas, TX 75202

We extend our congratulations to you on this award and look forward to working with you during the course of the demonstration.

Sincerely,

A solid black rectangular box redacting the signature of Herb B. Kuhn.

Herb B. Kuhn
Acting Deputy Administrator

Enclosure

ATTACHMENT B - CMS Approved Family Planning Waiver Codes for Louisiana "Take Charge" Program

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
LA	00851	ANES:TUBAL LIGATION/TRANSECTION		X	
	11975	INSERTION OR REINSERTION, IMPLANTABL		X	
	11976	REMOVAL WITHOUT REINSERTION, IMPLANT		X	
	11977	REMOVAL WITH REINSERTION, IMPLANTABL		X	
	36415	COLLECT VENOUS BLOOD BY VENIPUNCTURE		X	
	57170	DIAPHRAGM FITTING.WITH INSTRUCTIONS		X	
	58300	INSERT INTRAUTERINE DEVICE		X	
	58301	REMOVE INTRAUTERINE DEVICE		X	
	58600	DIVISION OF FALLOPIAN TUBES		X	
	58615	OCCLUSION OF FALLOPIAN TUBE, DEVICE		X	
	58670	LAPAROSCOPY, TUBAL CAUTERY		X	
	58671	LAPAROSCOPY, TUBAL BLOCK		X	
	62311	INJECTIONS; LUMBAR, SACRAL		X	
	62319	INJECT SPINE W/CATH L/S (CD)		X	
	71010	RADIOLOGIC EXAM, CHEST SINGLE VIEW			
	71020	RADIOLOGIC EXAM, CHEST TWO VIEWS			
	80048	BASIC METABOLIC PANEL		X	
	80050	GENERAL HEALTH SCREEN PANEL		X	
	80051	ELECTROLYTE PANEL		X	
	80061	LIPID PROFILE		X	
	81000	URINALYSIS WITH MICROSCOPY		X	
	81001	URINALYSIS, AUTO, W/SCOPE		X	
	81002	ROUTINE URINE ANALYSIS		X	
	81003	URINALYSIS, BY DIP STICK OR TABLET R		X	
	81005	URINALYSIS		X	
	81025	URINE PREG TEST-BY VISUAL COLOR COMP		X	
	82948	STICK ASSAY OF BLOOD GLUCOSE		X	
	82962	GLUCOSE, BLOOD, BY GLUCOSE MONITORIN		X	
	83020	ASSAY HEMOGLOBIN		X	
	83020	ASSAY HEMOGLOBIN		X	
	84520	ASSAY BUN		X	
	84550	ASSAY BLOOD URIC ACID		X	
	84702	GONADOTROPIN,CHORIONIC;QUANTITATIVE		X	
	84703	GONADOTROPIN,CHORIONIC;QUALITATIVE		X	
	85013	SPUN HEMATOCRIT		X	
	85014	BLOOD COUNT OTHER THAN SPUN HEMATOCR		X	
	85018	HEMOGLOBIN		X	
	85018	HEMOGLOBIN, COLORIMETRIC		X	
	86592	SYPHILIS TEST(S),QUALITATIVE		X	
	86593	SYPHILIS TEST, QUANTITATIVE		X	
	86631	ANTIBODY;CHLAMYDIA		X	
	86645	ANTIBODY;CYTOMEGALOVIRUS		X	
	86687	ANTIBODY; HTLV-I		X	
	86688	ANTIBODY; HTLV-II		X	
	86689	CONFIRMATORY TEST HYLV or HIV		X	
	86701	ANTIBODY; HIV-1		X	
	86702	ANTIBODY; HIV2		X	
	86703	ANTIBODY; HIV 1 AND 2 SINGLE ASSAY		X	
	87070	CULTURE SPECIMEN, BACTERIA		X	
	87075	CULTURE SPECIMEN, BACTERIA		X	
	87081	BACTERIA CULTURE SCREEN		X	
	87110	CULTURE,CHLAMYDIA		X	
	87110	CULTURE, CHLAMYDIA, ANY SOURCE		X	
	87210	SMEAR, STAIN & INTERPRET		X	
	87270	CHYLM D TRACH AG, DFA		X	
	87320	CHYLM D TRACH AG, EIA		X	
	87390	HIV-1 AG, EIA		X	
	87391	HIV-2 AG, EIA		X	
	87480	CANDIDA, DNA, DIR PROBE		X	
	87481	CANDIDA, DNA, AMP PROBE		X	
	87490	CHYLM D TRACH, DNA, DIR PROBE		X	
	87491	CHYLM D TRACH, DNA, AMP PROBE		X	
	87590	N.GONORRHOEAE, DNA, DIR PROB		X	
	87591	N.GONORRHOEAE, DNA, AMP PROB		X	
	87620	HPV, DNA, DIR PROBE		X	
	87621	HPV, DNA, AMP PROBE		X	
	87810	CHYLM D TRACH ASSAY W/OPTIC		X	
	87850	N. GONORRHOEAE ASSAY W/OPTIC		X	
	88108	CYTOPATHOLOGY,FLUIDS,WASHINGS		X	
	88141	CYTOPATH CERV/VAG INTERPRET		X	
	88142	CYTOPATH CERV/VAG THIN LAYER		X	
	88143	CYTPATH C/VAG T/LAYER REDO		X	
	88147	CYTPATH C/VAG AUTOMATED		X	
	88148	CYTPATH C/VAG AUTO RESCREEN		X	
	88150	CYTOPATHOLOGY, PAP SMEAR		X	
	88152	CYTOPATH CERV/VAG AUTO		X	

88153	CYTPATH C/VAG REDO	x
88154	CYTPATH C/VAG SELECT	x

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	88155	CYTOPATH,(PAP);W/ DEF.HORMONAL EVAL		X	
	88160	CYTOPATHOLOGY		X	
	88161	CYTOPATH . . . ; PREP, SCREEN INTERP.		X	
	88162	CYTOPATH . . . ; EXT. STUDY.+5 SLIDES, MULTI		X	
	88164	CYTPATH TBS C/VAG MANUAL		X	
	88165	CYTPATH TBS C/VAG REDO		X	
	88166	CYTPATH TBS C/VAG AUTO REDO		X	
	88167	CYTPATH TBS C/VAG SELECT		X	
	88173	FINE NEEDLE ASPIRATE.;;INTERP/REPORT		X	
	88174	CYTOPATH, C/VAG (ANY REP.SYSTEM)		X	
	88175	CYTOPATHOLOGY WITH SCREENING		X	
	88300	SURGICAL PATHOLOGY, GROSS		X	
	88302	SURGICAL PATHOLOGY, COMPLETE		X	
	88312	SPECIAL STAINS		X	
	88313	SPECIAL STAINS		X	
	90772	Therapeutic, prophylactic or diagnostic injection	X		
	90784	THERAPEUTIC INJECTION; IV		X	
	93000	ROUTINE ECG W/AT LEAST 12 LEADS		X	
	99201	OFFICE,NEW,PROBLEM, STRAIGHTFORWARD		X	
	99202	OFFICE,NEW PT,EXPANDED,STRAIGHTFORWARD		X	
	99203	OFFICE,NEW PT, DETAILED, LOW COMPLEX		X	
	99204	OFFICE,NEW PT, COMPREHEN, MOD COMPLX		X	
	99205	OFFICE,NEW PT, COMPREHEN, HIGH COMPLX		X	
	99211	OFFICE, EST PT, MINIMAL PROBLEMS		X	
	99212	OFFICE,EST PT, PROBLEM,STRAITFORWD		X	
	99213	OFFICE, EST PT, EXPANDED, LOW COMPLX		X	
	99214	OFFICE,EST PT, DETAILED, MOD COMPLX		X	
	99215	OFFICE,EST PT, COMPREHEN,HIGH COMPLX		X	
	99241	OFF CONSULT,NRE PT,PRBLM,STRTFWD		X	
	99242	OFF CONSULT,NRE PT,XPND PBLM, STRTFWD		X	
	99243	OFF CNSLT,NRE PT,DTLD, LO CMLPLY		X	
	99244	OFF CNSLT,NRE PT,CMPHSV,MOD CMLPLY		X	
	99245	OFF CNSLT,NRE PT,CMPHSV,HI CMLPLY		X	
	A4267	CONTRACEP SUPPLY/MALE CONDOM, EACH		X	
	A4268	CONTRACEP SUPPLY/FEMALE CONDOM, EACH		X	
	A4269	CONTRACEPTIVE SUPPLY, SPERMACIDE		X	
	HR250	PHARMACY,GENERAL CLASSIFICATION		X	NO
	HR258	PHARMACY,IV SOLUTIONS		X	NO
	HR259	PHARMACY, OTHER PHARMACY		X	NO
	HR260	IV THERAPY		X	NO
	HR270	MED/SURG SUPPLY/DEVICE-GEN. CLS		X	NO
	HR271	TEMPKIT/PROBE COVERS/SERVICE		X	NO
	HR272	STERILE SUPPLY		X	NO
	HR320	RADIOLOGY-DIAGNOSTIC GEN CLASS		X	YES(non-specific)
	HR324	CHEST X-RAY		X	YES(non-specific)
	HR402	ULTRASOUNMD		X	YES(non-specific)
	HR490	AMBULATORY SURGICAL CARE GENERAL		X	NO
	HR760	TREATMENT/OBSERVATION ROOM		X	NO
	HR920	OTHER DIAG SERV GEN CLASSIFICATION		X	NO
	HR925	PREGNANCY TEST		X	YES(non-specific)
	J1055	DEPO-PROVERA INJ 150MG		X	
	J1056	LUNELLE MONTHLY CONTRACEPTION INJ		X	
	J7300	INTRAUTERINE COPPER CONTRACEPTIVE		X	
	J7302	MIRENA		X	
	Q0091	SCREENING PAPANICOLAOU (PAP) SMEAR		X	
	Q0111	WET MOUNTS,PREPARATIONS OF VAGINAL		X	
	Q0112	POTASSIUM MYDROXIDE PREPARATIONS		X	
	S4993	CONTRACEP PILLS/BIRTH CONTROL-1 MTH		X	
	T1001	NURSING ASSESSMENT		X	
	T1002	RN SERVICES		X	
	T1015	Encounter for Native American Services		X	
	00008-0056-01	NORGESTREL-ETHINYL ESTR	X		
	00008-0056-02	NORGESTREL-ETHINYL ESTR	X		
	00008-0062-01	NORGESTREL	X		
	00008-0062-02	NORGESTREL	X		
	00008-0075-01	LEVONORGESTREL-ETH ESTR	X		
	00008-0075-02	LEVONORGESTREL-ETH ESTR	X		
	00008-0078-01	NORGESTREL-ETHINYL ESTR	X		
	00008-0078-02	NORGESTREL-ETHINYL ESTR	X		
	00008-0912-02	LEVONORGESTREL-ETH ESTR	X		
	00008-2511-01	NORGESTREL-ETHINYL ESTR	X		
	00008-2511-02	NORGESTREL-ETHINYL ESTR	X		
	00008-2514-01	NORGESTREL-ETHINYL ESTR	X		
	00008-2514-02	NORGESTREL-ETHINYL ESTR	X		
	00008-2514-03	NORGESTREL-ETHINYL ESTR	X		
	00008-2533-01	LEVONORGESTREL-ETH ESTR	X		

Explanations:
1) NO = No HCPCS code required
2) YES (non-specific)=Any HCPCS codes can be used.

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	00008-2533-02	LEVONORGESTREL-ETH ESTR	X		
	00008-2533-03	LEVONORGESTREL-ETH ESTR	X		
	00008-2535-01	LEVONORGESTREL-ETH ESTR	X		
	00008-2535-05	LEVONORGESTREL-ETH ESTR	X		
	00008-2536-01	LEVONORGESTREL-ETH ESTR	X		
	00008-2536-03	LEVONORGESTREL-ETH ESTR	X		
	00008-2536-05	LEVONORGESTREL-ETH ESTR	X		
	00008-2564-01	LEVONORGESTREL	X		
	00008-2576-01	LEVONORGESTREL-ETH ESTR	X		
	00008-2576-02	LEVONORGESTREL-ETH ESTR	X		
	00009-0746-30	MEDROXYPROGESTERONE ACE	X		
	00009-0746-35	MEDROXYPROGESTERONE ACE	X		
	00009-3484-04	ESTRAD CYP/M-PROGEST AC	X		
	00009-3484-05	ESTRAD CYP/M-PROGEST AC	X		
	00009-3484-06	ESTRAD CYP/M-PROGEST AC	X		
	00009-3484-10	ESTRAD CYP/M-PROGEST AC	X		
	00009-4709-01	MEDROXYPROGESTERONE ACE	X		
	00009-7376-01	MEDROXYPROGESTERONE ACE	X		
	00009-7376-02	MEDROXYPROGESTERONE ACE	X		
	00009-7376-03	MEDROXYPROGESTERONE ACE	X		
	00009-7376-04	MEDROXYPROGESTERONE ACE	X		
	00025-0071-07	ETHYNODIOL D-ETHINYL ES	X		
	00025-0071-24	ETHYNODIOL D-ETHINYL ES	X		
	00025-0081-09	ETHYNODIOL D-ETHINYL ES	X		
	00025-0081-24	ETHYNODIOL D-ETHINYL ES	X		
	00025-0081-84	ETHYNODIOL D-ETHINYL ES	X		
	00025-0151-07	ETHYNODIOL D-ETHINYL ES	X		
	00025-0151-24	ETHYNODIOL D-ETHINYL ES	X		
	00025-0161-09	ETHYNODIOL D-ETHINYL ES	X		
	00025-0161-24	ETHYNODIOL D-ETHINYL ES	X		
	00025-0161-84	ETHYNODIOL D-ETHINYL ES	X		
	00025-0235-06	NORETHINDRONE	X		
	00025-0263-06	NORETHINDRONE-MESTRANOL	X		
	00025-0272-06	NORETHINDRONE-ETHINYL E	X		
	00025-0272-12	NORETHINDRONE-ETHINYL E	X		
	00025-0274-06	NORETHINDRONE-ETHINYL E	X		
	00025-0274-12	NORETHINDRONE-ETHINYL E	X		
	00045-0526-60	OXYCODONE HCL/ACETAMINOPHEN			
	00045-0526-79	OXYCODONE HCL/ACETAMINOPHEN			
	00052-0261-06	DESOGESTREL-ETHINYL EST	X		
	00052-0269-06	NORETHINDRONE-ETHINYL E	X		
	00052-0273-01	ETONOGESTREL/ETHINYL ES	X		
	00052-0281-06	DESOG-ET ESTRA/ETHIN ES	X		
	00052-0283-06	DESOGESTREL-ETHINYL EST	X		
	00054-2795-25	OXYCODONE HCL/ACETAMINOPHEN			
	00062-1251-01	NORGESTIMATE-ETHINYL ES	X		
	00062-1251-15	NORGESTIMATE-ETHINYL ES	X		
	00062-1332-00	NORETHINDRONE-MESTRANOL	X		
	00062-1332-15	NORETHINDRONE-MESTRANOL	X		
	00062-1332-20	NORETHINDRONE-MESTRANOL	X		
	00062-1411-01	NORETHINDRONE	X		
	00062-1411-16	NORETHINDRONE	X		
	00062-1714-15	NORETHINDRONE-ETHINYL E	X		
	00062-1714-20	NORETHINDRONE-ETHINYL E	X		
	00062-1714-25	NORETHINDRONE-ETHINYL E	X		
	00062-1714-27	NORETHINDRONE-ETHINYL E	X		
	00062-1760-15	NORETHINDRONE-ETHINYL E	X		
	00062-1761-15	NORETHINDRONE-ETHINYL E	X		
	00062-1761-20	NORETHINDRONE-ETHINYL E	X		
	00062-1771-15	NORETHINDRONE-ETHINYL E	X		
	00062-1780-15	NORETHINDRONE-ETHINYL E	X		
	00062-1780-22	NORETHINDRONE-ETHINYL E	X		
	00062-1781-15	NORETHINDRONE-ETHINYL E	X		
	00062-1781-20	NORETHINDRONE-ETHINYL E	X		
	00062-1781-22	NORETHINDRONE-ETHINYL E	X		
	00062-1795-15	DESOGESTREL-ETHINYL EST	X		
	00062-1796-15	DESOGESTREL-ETHINYL EST	X		
	00062-1900-15	NORGESTIMATE-ETHINYL ES	X		
	00062-1901-15	NORGESTIMATE-ETHINYL ES	X		
	00062-1902-15	NORGESTIMATE-ETHINYL ES	X		
	00062-1903-15	NORGESTIMATE-ETHINYL ES	X		
	00062-1920-01	ETHINYL ESTRADIOL/NOREL	X		
	00062-1920-15	ETHINYL ESTRADIOL/NOREL	X		
	00062-3133-01	NONOXYNOL 9	X		
	00062-3133-02	NONOXYNOL 9	X		
	00062-3180-11	NONOXYNOL 9	X		
	00062-3180-12	NONOXYNOL 9	X		
	00062-3185-01	NONOXYNOL 9	X		

00062-3250-01	NONOXYNOL 9	X
00062-3250-02	NONOXYNOL 9	X
00062-3255-01	NONOXYNOL 9	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	00062-3301-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3302-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3303-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3304-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3305-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3306-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3307-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3308-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3309-00	DIAPHRAGMS, ARC-SPRING	X		
	00062-3341-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3342-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3343-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3344-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3345-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3346-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3347-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3348-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3349-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3350-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3351-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3352-00	DIAPHRAGMS, COIL SPRING	X		
	00062-3381-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3382-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3383-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3384-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3385-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3386-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3387-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3388-00	DIAPHRAGMS, FLAT SPRING	X		
	00062-3389-00	DIAPHRAGMS, FLAT SPRING	X		
	00071-0913-15	NORETH A-ET ESTRA/FE FU	X		
	00071-0913-38	NORETH A-ET ESTRA/FE FU	X		
	00071-0913-45	NORETH A-ET ESTRA/FE FU	X		
	00071-0913-47	NORETH A-ET ESTRA/FE FU	X		
	00071-0913-48	NORETH A-ET ESTRA/FE FU	X		
	00071-0915-47	NORETHINDRONE A-E ESTRA	X		
	00071-0915-48	NORETHINDRONE A-E ESTRA	X		
	00071-0916-47	NORETHINDRONE A-E ESTRA	X		
	00071-0916-48	NORETHINDRONE A-E ESTRA	X		
	00071-0917-45	NORETH A-ET ESTRA/FE FU	X		
	00071-0917-47	NORETH A-ET ESTRA/FE FU	X		
	00071-0917-48	NORETH A-ET ESTRA/FE FU	X		
	00071-0928-15	NORETH A-ET ESTRA/FE FU	X		
	00071-0928-47	NORETH A-ET ESTRA/FE FU	X		
	00085-0050-01	NONOXYNOL 9	X		
	00085-0050-02	NONOXYNOL 9	X		
	00085-0050-03	NONOXYNOL 9	X		
	00085-0050-04	NONOXYNOL 9	X		
	00085-0050-05	NONOXYNOL 9	X		
	00085-0439-01	NONOXYNOL 9	X		
	00085-0439-02	NONOXYNOL 9	X		
	00087-0578-41	NORETHINDRONE-ETHINYL E	X		
	00087-0579-41	NORETHINDRONE-ETHINYL E	X		
	00087-0583-42	NORETHINDRONE-ETHINYL E	X		
	00093-0490-01	PROPOXYPHENE/ACETAMINOPHEN	X		
	00093-0490-05	PROPOXYPHENE/ACETAMINOPHEN			
	00093-0890-01	PROPOXYPHENE/ACETAMINOPHEN			
	00093-0890-05	PROPOXYPHENE/ACETAMINOPHEN			
	00093-5315-28	NORGESTIMATE-ETHINYL ES	X		
	00093-5315-81	NORGESTIMATE-ETHINYL ES	X		
	00093-5316-28	NORGESTIMATE-ETHINYL ES	X		
	00093-5316-81	NORGESTIMATE-ETHINYL ES			
	00228-2085-50	PROPOXYPHENE/ACETAMINOPHEN			
	00234-0131-00	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-50	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-55	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-60	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-65	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-70	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-75	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-80	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-85	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-90	DIAPHRAGMS, COIL SPRING	X		
	00234-0131-95	DIAPHRAGMS, COIL SPRING	X		
	00234-0136-00	DIAPHRAGMS, ARC-SPRING	X		
	00234-0136-60	DIAPHRAGMS, ARC-SPRING	X		
	00234-0136-65	DIAPHRAGMS, ARC-SPRING	X		
	00234-0136-70	DIAPHRAGMS, ARC-SPRING	X		

00234-0136-75	DIAPHRAGMS, ARC-SPRING	X
00234-0136-80	DIAPHRAGMS, ARC-SPRING	X
00234-0136-85	DIAPHRAGMS, ARC-SPRING	X
00234-0136-90	DIAPHRAGMS, ARC-SPRING	X
00234-0136-95	DIAPHRAGMS, ARC-SPRING	X
00247-0591-01	MEDROXYPROGESTERONE ACE	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	00247-1003-28	NORGESTREL-ETHINYL ESTR	X		
	00247-1004-21	NORGESTREL-ETHINYL ESTR	X		
	00339-6518-99	DESOGESTREL-ETHINYL EST	X		
	00378-0155-01	PROPOXYPHENE/ACETAMINOPHEN			
	00378-0155-05	PROPOXYPHENE/ACETAMINOPHEN			
	00396-4010-00	NONOXYNOL 9	X		
	00396-4010-60	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-65	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-70	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-75	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-80	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-85	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-90	DIAPHRAGMS, WIDE SEAL	X		
	00396-4010-95	DIAPHRAGMS, WIDE SEAL	X		
	00406-0532-01	OXYCODONE HCL/ACETAMINOPHEN			
	00406-0532-05	OXYCODONE HCL/ACETAMINOPHEN			
	00406-1721-01	PROPOXYPHENE/ACETAMINOPHEN			
	00406-1721-05	PROPOXYPHENE/ACETAMINOPHEN			
	00406-1721-10	PROPOXYPHENE/ACETAMINOPHEN			
	00406-1772-01	PROPOXYPHENE/ACETAMINOPHEN			
	00406-1772-05	PROPOXYPHENE/ACETAMINOPHEN			
	00406-1772-10	PROPOXYPHENE/ACETAMINOPHEN			
	00430-0570-14	NORETH A-ET ESTRA/FE FU	X		
	00430-0580-14	NORETHINDRONE-ETHINYL E	X		
	00430-0581-14	NORETHINDRONE-ETHINYL E	X		
	00430-0582-14	NORETHINDRONE-ETHINYL E	X		
	00430-0583-11	NORETHINDRONE-ETHINYL E	X		
	00430-0585-14	NORETHINDRONE-ETHINYL E	X		
	00536-9995-12	CONDOMS, LATEX, LUBRICA	X		
	00537-6617-44	NORETHINDRONE-MESTRANOL	X		
	00537-6618-48	NORETHINDRONE-MESTRANOL	X		
	00555-0344-58	NORETHINDRONE	X		
	00555-0658-02	OXYCODONE HCL/ACETAMINOPHEN			
	00555-0715-58	NORETHINDRONE	X		
	00555-9008-58	NORETHINDRONE-ETHINYL E	X		
	00555-9008-67	NORETHINDRONE-ETHINYL E	X		
	00555-9009-42	NORETHINDRONE-ETHINYL E	X		
	00555-9009-57	NORETHINDRONE-ETHINYL E	X		
	00555-9010-58	NORETHINDRONE-ETHINYL E	X		
	00555-9012-58	NORETHINDRONE-ETHINYL E	X		
	00555-9014-58	LEVONORGESTREL-ETH ESTR	X		
	00555-9014-67	LEVONORGESTREL-ETH ESTR	X		
	00555-9016-58	NORGESTIMATE-ETHINYL ES	X		
	00555-9018-58	NORGESTIMATE-ETHINYL ES	X		
	00555-9020-58	LEVONORGESTREL-ETH ESTR	X		
	00555-9025-42	NORETHINDRONE A-E ESTRA	X		
	00555-9025-57	NORETHINDRONE A-E ESTRA	X		
	00555-9026-58	NORETH A-ET ESTRA/FE FU	X		
	00555-9027-57	NORETHINDRONE A-E ESTRA	X		
	00555-9028-58	NORETH A-ET ESTRA/FE FU	X		
	00555-9043-58	DESOGESTREL-ETHINYL EST	X		
	00555-9045-58	LEVONORGESTREL-ETH ESTR	X		
	00555-9047-58	LEVONORGESTREL-ETH ESTR	X		
	00555-9049-58	NORGESTREL-ETHINYL ESTR	X		
	00555-9050-58	DESOG-ET ESTRA/ETHIN ES	X		
	00555-9051-58	DESOGESTREL-ETHINYL EST	X		
	00555-9051-67	DESOGESTREL-ETHINYL EST	X		
	00555-9064-67	ETHYNODIOL D-ETHINYL ES	X		
	00555-9066-58	NORETHINDRONE-ETHINYL E	X		
	00555-9066-67	NORETHINDRONE-ETHINYL E	X		
	00573-3301-09	NONOXYNOL 9	X		
	00573-3301-18	NONOXYNOL 9	X		
	00591-0737-01	OXYCODONE HCL/ACETAMINOPHEN			
	00591-0737-05	OXYCODONE HCL/ACETAMINOPHEN			
	00603-4997-21	OXYCODONE HCL/ACETAMINOPHEN			
	00603-5466-21	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5466-28	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5466-32	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5467-21	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5467-28	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5467-32	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5468-02	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5468-21	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5468-28	PROPOXYPHENE/ACETAMINOPHEN			
	00603-5468-32	PROPOXYPHENE/ACETAMINOPHEN			
	00703-6801-01	MEDROXYPROGESTERONE ACE	X		
	00703-6801-04	MEDROXYPROGESTERONE ACE	X		
	00703-6811-21	MEDROXYPROGESTERONE ACE	X		

00905-0291-28	LEVONORGESTREL-ETH ESTR	X
00904-2281-40	PROPOXYPHENE/ACETAMINOPHEN	
02340-0071-00	CONDOMS, LATEX, LUBRICA	X
02340-0071-67	CONDOMS, LATEX, LUBRICA	X
02340-0082-40	CONDOMS, LATEX, LUBRICA	X
02340-0128-00	CONDOMS, LATEX, LUBRICA	X
05632-0830-10	CONDOMS, LATEX, LUBRICA	X
05632-0830-15	CONDOMS, LATEX, LUBRICA	X
05632-0830-20	CONDOMS, LATEX, LUBRICA	X
05632-0830-25	CONDOMS, LATEX, LUBRICA	X
05632-0830-30	CONDOMS, LATEX, LUBRICA	X
05632-0830-35	CONDOMS, LATEX, LUBRICA	X
05632-0830-40	CONDOMS, LATEX, LUBRICA	X
05632-0830-45	CONDOMS, LATEX, LUBRICA	X
05632-0830-50	CONDOMS, LATEX, NON-LUB	X
05632-0830-55	CONDOMS, LATEX, NON-LUB	X
05632-0840-10	CONDOMS, LATEX, LUBRICA	X
05632-0840-15	CONDOMS, LATEX, LUBRICA	X
05632-0840-20	CONDOMS, LATEX, LUBRICA	X
05632-0840-25	CONDOMS, LATEX, LUBRICA	X
05632-0840-30	CONDOMS, LATEX, LUBRICA	X
05632-0840-35	CONDOMS, LATEX, LUBRICA	X
05632-0840-40	CONDOMS, LATEX, LUBRICA	X
08137-0089-08	NONOXYNOL 9	X
08217-1582-22	CERVICAL CAP	X
08217-1582-25	CERVICAL CAP	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	08217-1582-28	CERVICAL CAP	X		
	08217-1582-31	CERVICAL CAP	X		
	08388-9110-12	CONDOMS, LATEX, LUBRICA	X		
	08388-9130-12	CONDOMS, LATEX, LUBRICA	X		
	08388-9403-05	CONDOMS, FEMALE	X		
	08507-1001-01	CONTRACEPT BARRIER DEV,	X		
	11423-0070-00	CONDOMS, FEMALE	X		
	11423-0070-70	CONDOMS, FEMALE	X		
	11423-0070-90	CONDOMS, FEMALE	X		
	11926-0221-12	NONOXYNOL 9	X		
	11926-0221-24	NONOXYNOL 9	X		
	12277-0561-03	NONOXYNOL 9	X		
	12277-0561-06	NONOXYNOL 9	X		
	16169-0010-03	CONDOMS, LATEX, NON-LUB	X		
	16169-0010-12	CONDOMS, LATEX, NON-LUB	X		
	16169-0020-03	CONDOMS, LATEX, NON-LUB	X		
	16169-0020-12	CONDOMS, LATEX, NON-LUB	X		
	16169-0030-03	CONDOMS, LATEX, LUBRICA	X		
	16169-0030-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0040-03	CONDOMS, LATEX, LUBRICA	X		
	16169-0040-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0050-03	CONDOMS, LATEX, NON-LUB	X		
	16169-0050-12	CONDOMS, LATEX, NON-LUB	X		
	16169-0050-24	CONDOMS, LATEX, NON-LUB	X		
	16169-0060-03	CONDOMS, LATEX, LUBRICA	X		
	16169-0060-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0060-24	CONDOMS, LATEX, LUBRICA	X		
	16169-0070-03	CONDOMS, LATEX, LUBRICA	X		
	16169-0070-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0080-03	CONDOMS, LATEX, LUBRICA	X		
	16169-0080-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0110-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0130-12	CONDOMS, LATEX, LUBRICA	X		
	16169-0403-03	CONDOMS, FEMALE	X		
	16169-0403-05	CONDOMS, FEMALE	X		
	17314-4231-01	PROGESTERONE	X		
	17714-0113-12	CONDOMS, LATEX, LUBRICA	X		
	21406-0015-06	NONOXYNOL 9	X		
	21406-0030-01	NONOXYNOL 9	X		
	22600-0093-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0640-93	CONDOMS, LATEX, NON-LUB	X		
	22600-0640-96	CONDOMS, LATEX, NON-LUB	X		
	22600-0641-03	CONDOMS, LATEX, LUBRICA	X		
	22600-0641-06	CONDOMS, LATEX, LUBRICA	X		
	22600-0642-03	CONDOMS, LATEX, LUBRICA	X		
	22600-0642-12	CONDOMS, LATEX, LUBRICA	X		
	22600-0645-03	CONDOMS, LATEX, LUBRICA	X		
	22600-0645-12	CONDOMS, LATEX, LUBRICA	X		
	22600-0647-12	CONDOMS, LATEX, LUBRICA	X		
	22600-0906-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0906-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0907-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0908-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0908-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0909-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0910-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0912-22	CONDOMS, LATEX, LUBRICA	X		
	22600-0912-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0913-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0914-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0915-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0915-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0916-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0917-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0918-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0919-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0920-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0922-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0922-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0923-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0923-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0926-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0926-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0927-20	CONDOMS, LATEX, LUBRICA	X		
	22600-0927-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0929-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0930-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0930-70	CONDOMS, LATEX, LUBRICA	X		

22600-0931-50	CONDOMS, LATEX, LUBRICA	X
22600-0931-70	CONDOMS, LATEX, LUBRICA	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	22600-0932-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0932-70	CONDOMS, LATEX, LUBRICA	X		
	22600-0933-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0937-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0937-70	CONDOMS, LATEX, LUBRICA	X		
	22600-0938-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0939-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0940-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0941-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0945-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0946-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0947-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0949-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0950-00	CONDOMS, LATEX, NON-LUB	X		
	22600-0951-00	CONDOMS, LATEX, LUBRICA	X		
	22600-0952-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0956-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0957-40	CONDOMS, LATEX, LUBRICA	X		
	22600-0958-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0959-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0960-60	CONDOMS, LATEX, NON-LUB	X		
	22600-0967-60	CONDOMS, LATEX, NON-LUB	X		
	22600-0970-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0972-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0977-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0979-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0980-50	CONDOMS, NON-LATEX, NON	X		
	22600-0987-50	CONDOMS, NON-LATEX, LUB	X		
	22600-0990-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0991-50	CONDOMS, LATEX, LUBRICA	X		
	22600-0997-50	CONDOMS, LATEX, NON-LUB	X		
	22600-0998-50	CONDOMS, LATEX, LUBRICA	X		
	23858-0112-12	CONDOMS, LATEX, LUBRICA	X		
	26893-0100-02	CONDOMS, LATEX, LUBRICA	X		
	26893-0100-92	CONDOMS, LATEX, LUBRICA	X		
	26893-0101-02	CONDOMS, LATEX, LUBRICA	X		
	26893-0101-92	CONDOMS, LATEX, LUBRICA	X		
	28373-0200-03	CONDOMS, LATEX, LUBRICA	X		
	28373-0200-12	CONDOMS, LATEX, LUBRICA	X		
	28373-0210-00	CONDOMS, LATEX, LUBRICA	X		
	28373-0310-00	CONDOMS, LATEX, LUBRICA	X		
	28373-0310-03	CONDOMS, LATEX, LUBRICA	X		
	28373-0310-12	CONDOMS, LATEX, LUBRICA	X		
	28373-0410-00	CONDOMS, LATEX, LUBRICA	X		
	28373-0510-00	CONDOMS, LATEX, LUBRICA	X		
	28373-0510-12	CONDOMS, LATEX, LUBRICA	X		
	28373-0700-03	CONDOMS, LATEX, LUBRICA	X		
	28373-0700-06	CONDOMS, LATEX, LUBRICA	X		
	28373-0700-12	CONDOMS, LATEX, LUBRICA	X		
	28373-0710-00	CONDOMS, LATEX, LUBRICA	X		
	28373-0900-03	CONDOMS, LATEX, LUBRICA	X		
	28373-0900-06	CONDOMS, LATEX, LUBRICA	X		
	28373-0900-12	CONDOMS, LATEX, LUBRICA	X		
	28373-0910-00	CONDOMS, LATEX, LUBRICA	X		
	30716-0161-36	CONDOMS, LATEX, LUBRICA	X		
	30716-0401-18	CONDOMS, LATEX, LUBRICA	X		
	30716-0801-28	CONDOMS, LATEX, LUBRICA	X		
	30716-0801-30	CONDOMS, LATEX, LUBRICA	X		
	41250-0528-13	CONDOMS, LATEX, LUBRICA	X		
	42037-0129-24	NONOXYNOL 9	X		
	43820-0003-01	CONDOMS, LATEX, LUBRICA	X		
	48723-0001-11	NONOXYNOL 9	X		
	48723-0003-33	NONOXYNOL 9	X		
	48723-0006-66	NONOXYNOL 9	X		
	50419-0402-03	ETHINYL ESTRADIOL/DROSP	X		
	50419-0406-03	LEVONORGESTREL-ETH ESTR	X		
	50419-0408-03	LEVONORGESTREL-ETH ESTR	X		
	50419-0410-21	LEVONORGESTREL-ETH ESTR	X		
	50419-0411-12	LEVONORGESTREL-ETH ESTR	X		
	50419-0411-28	LEVONORGESTREL-ETH ESTR	X		
	50419-0421-01	LEVONORGESTREL	X		
	50419-0432-03	LEVONORGESTREL-ETH ESTR	X		
	50419-0432-06	LEVONORGESTREL-ETH ESTR	X		
	50419-0433-03	LEVONORGESTREL-ETH ESTR	X		
	50419-0433-06	LEVONORGESTREL-ETH ESTR	X		
	50419-0433-12	LEVONORGESTREL-ETH ESTR	X		
	50486-0221-12	NONOXYNOL 9	X		
	50907-0380-06	INTRA-UTERINE DEVICE (I	X		

50907-0380-07	INTRA-UTERINE DEVICE (I	X
51079-0322-20	PROPOXYPHENE/ACETAMINOPHEN	
51079-0322-21	PROPOXYPHENE/ACETAMINOPHEN	
51079-0322-56	PROPOXYPHENE/ACETAMINOPHEN	
51285-0017-28	LEVONORGESTREL-ETH ESTR	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	51285-0038-93	LEVONORGESTREL	X		
	51285-0058-66	LEVONORGESTREL-ETH ESTR	X		
	51285-0079-97	NORETHINDRONE A-E ESTRA	X		
	51285-0080-70	NORETH A-ET ESTRA/FE FU	X		
	51285-0081-98	NORETH A-ET ESTRA/FE FU	X		
	51285-0082-97	NORETHINDRONE A-E ESTRA	X		
	51285-0083-70	NORETH A-ET ESTRA/FE FU	X		
	51285-0084-98	NORETH A-ET ESTRA/FE FU	X		
	51285-0091-58	LEVONORGESTREL-ETH ESTR	X		
	51285-0114-58	DESOG-ET ESTRA/ETHIN ES	X		
	51285-0514-28	LEVONORGESTREL-ETH ESTR	X		
	51285-0546-28	NORGESTREL-ETHINYL ESTR	X		
	51285-0576-28	DESOGESTREL-ETHINYL EST	X		
	51672-2041-04	NONOXYNOL 9	X		
	51709-0006-05	CONDOMS, LATEX, LUBRICA	X		
	51709-0006-06	CONDOMS, LATEX, LUBRICA	X		
	52152-0041-02	OXYCODONE HCL/ACETAMINOPHEN			
	52544-0219-28	NORETHINDRONE-ETHINYL E	X		
	52544-0235-28	NORETHINDRONE	X		
	52544-0254-28	NORETHINDRONE-ETHINYL E	X		
	52544-0259-28	NORETHINDRONE-ETHINYL E	X		
	52544-0265-28	NORETHINDRONE-MESTRANOL	X		
	52544-0265-31	NORETHINDRONE-MESTRANOL	X		
	52544-0274-28	NORETHINDRONE-ETHINYL E	X		
	52544-0277-21	LEVONORGESTREL-ETH ESTR	X		
	52544-0279-28	LEVONORGESTREL-ETH ESTR	X		
	52544-0291-28	LEVONORGESTREL-ETH ESTR	X		
	52544-0383-28	ETHYNODIOL D-ETHINYL ES	X		
	52544-0384-28	ETHYNODIOL D-ETHINYL ES	X		
	52544-0507-21	NORETHINDRONE-ETHINYL E	X		
	52544-0508-21	NORETHINDRONE-ETHINYL E	X		
	52544-0510-21	NORETHINDRONE-MESTRANOL	X		
	52544-0526-28	NORGESTIMATE-ETHINYL ES	X		
	52544-0532-21	ETHYNODIOL D-ETHINYL ES	X		
	52544-0533-21	ETHYNODIOL D-ETHINYL ES	X		
	52544-0550-28	NORETHINDRONE-ETHINYL E	X		
	52544-0552-28	NORETHINDRONE-ETHINYL E	X		
	52544-0553-21	NORETHINDRONE-ETHINYL E	X		
	52544-0554-28	NORETHINDRONE-ETHINYL E	X		
	52544-0556-28	NORETHINDRONE-MESTRANOL	X		
	52544-0629-28	NORETHINDRONE	X		
	52544-0630-28	NORETH A-ET ESTRA/FE FU	X		
	52544-0631-28	NORETH A-ET ESTRA/FE FU	X		
	52544-0847-21	NORGESTREL-ETHINYL ESTR	X		
	52544-0847-28	NORGESTREL-ETHINYL ESTR	X		
	52544-0848-28	NORGESTREL-ETHINYL ESTR	X		
	52544-0892-28	NORETHINDRONE	X		
	52544-0935-28	NORGESTIMATE-ETHINYL ES	X		
	52544-0936-28	NORETHINDRONE-ETHINYL E	X		
	52544-0949-28	LEVONORGESTREL-ETH ESTR	X		
	52544-0950-21	NORETHINDRONE A-E ESTRA	X		
	52544-0951-21	NORETHINDRONE A-E ESTRA	X		
	52544-0954-28	DESOGESTREL-ETHINYL EST	X		
	52925-0112-01	NONOXYNOL 9	X		
	52925-0112-02	NONOXYNOL 9	X		
	52925-0112-03	NONOXYNOL 9	X		
	52925-0112-04	NONOXYNOL 9	X		
	52925-0312-14	NONOXYNOL 9	X		
	52959-0460-04	NORGESTREL-ETHINYL ESTR	X		
	54569-0673-00	ETHYNODIOL D-ETHINYL ES	X		
	54569-0679-00	NORGESTREL-ETHINYL ESTR	X		
	54569-0685-00	NORETHINDRONE-ETHINYL E	X		
	54569-0689-00	NORETHINDRONE-ETHINYL E	X		
	54569-0689-01	NORETHINDRONE-ETHINYL E	X		
	54569-0690-00	NORGESTREL-ETHINYL ESTR	X		
	54569-0695-00	LEVONORGESTREL-ETH ESTR	X		
	54569-0695-01	LEVONORGESTREL-ETH ESTR	X		
	54569-1352-00	DIAPHRAGMS, ARC-SPRING	X		
	54569-1353-00	DIAPHRAGMS, ARC-SPRING	X		
	54569-1354-00	DIAPHRAGMS, ARC-SPRING	X		
	54569-1439-00	LEVONORGESTREL-ETH ESTR	X		
	54569-1766-00	NORETHINDRONE-ETHINYL E	X		
	54569-2397-00	NORETHINDRONE-ETHINYL E	X		
	54569-2397-01	NORETHINDRONE-ETHINYL E	X		
	54569-3254-01	NORETH A-ET ESTRA/FE FU	X		
	54569-3701-00	MEDROXYPROGESTERONE ACE	X		
	54569-3844-00	LEVONORGESTREL-ETH ESTR	X		
	54569-4222-00	DESOGESTREL-ETHINYL EST	X		

54569-4222-01	DESOGESTREL-ETHINYL EST	X
54569-4269-00	NORGESTIMATE-ETHINYL ES	X
54569-4273-00	NORGESTIMATE-ETHINYL ES	X
54569-4273-01	NORGESTIMATE-ETHINYL ES	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	54569-4710-00	LEVONORGESTREL-ETH ESTR	X		
	54569-4817-00	ETHYNODIOL D-ETHINYL ES	X		
	54569-4878-00	DESOGESTREL-ETHINYL EST	X		
	54569-4878-01	DESOGESTREL-ETHINYL EST	X		
	54569-4890-00	DESOG-ET ESTRA/ETHIN ES	X		
	54569-4904-00	MEDROXYPROGESTERONE ACE	X		
	54569-4984-00	NORETHINDRONE	X		
	54569-4997-00	LEVONORGESTREL-ETH ESTR	X		
	54569-4998-00	NORGESTREL-ETHINYL ESTR	X		
	54569-4999-00	NORETHINDRONE-ETHINYL E	X		
	54569-5115-00	LEVONORGESTREL-ETH ESTR	X		
	54569-5161-00	NORETHINDRONE	X		
	54569-5272-00	ESTRAD CYP/M-PROGEST AC	X		
	54569-5342-00	NONOXYNOL 9	X		
	54569-5343-00	LEVONORGESTREL	X		
	54569-5349-00	ETHINYL ESTRADIOL/DROSP	X		
	54569-5358-00	NORETHINDRONE-ETHINYL E	X		
	54569-5413-00	ETHINYL ESTRADIOL/NOREL	X		
	54569-5433-00	ESTRAD CYP/M-PROGEST AC	X		
	54569-5493-00	NORGESTIMATE-ETHINYL ES	X		
	54569-5493-02	NORGESTIMATE-ETHINYL ES	X		
	54569-5527-00	MEDROXYPROGESTERONE ACE	X		
	54569-5551-00	NORGESTIMATE-ETHINYL ES	X		
	54765-0380-01	INTRA-UTERINE DEVICE (I	X		
	54765-0380-05	INTRA-UTERINE DEVICE (I	X		
	54868-0404-00	ETHYNODIOL D-ETHINYL ES	X		
	54868-0428-00	NORGESTREL-ETHINYL ESTR	X		
	54868-0442-00	NORETHINDRONE-ETHINYL E	X		
	54868-0443-00	NORETHINDRONE-ETHINYL E	X		
	54868-0502-00	NORETH A-ET ESTRA/FE FU	X		
	54868-0507-00	LEVONORGESTREL-ETH ESTR	X		
	54868-0508-00	NORETHINDRONE-ETHINYL E	X		
	54868-0508-01	NORETHINDRONE-ETHINYL E	X		
	54868-0509-01	NORETHINDRONE-ETHINYL E	X		
	54868-0516-00	NORETHINDRONE-ETHINYL E	X		
	54868-0518-00	LEVONORGESTREL-ETH ESTR	X		
	54868-0518-01	LEVONORGESTREL-ETH ESTR	X		
	54868-0525-00	NORETHINDRONE-ETHINYL E	X		
	54868-0528-01	NORETHINDRONE-ETHINYL E	X		
	54868-1276-00	NORGESTREL-ETHINYL ESTR	X		
	54868-1512-00	NORETH A-ET ESTRA/FE FU	X		
	54868-1564-00	LEVONORGESTREL-ETH ESTR	X		
	54868-2316-00	LEVONORGESTREL-ETH ESTR	X		
	54868-2606-00	NORGESTIMATE-ETHINYL ES	X		
	54868-2701-00	DESOGESTREL-ETHINYL EST	X		
	54868-3328-00	LEVONORGESTREL-ETH ESTR	X		
	54868-3613-00	MEDROXYPROGESTERONE ACE	X		
	54868-3772-00	NORETHINDRONE-ETHINYL E	X		
	54868-3790-00	ETHYNODIOL D-ETHINYL ES	X		
	54868-3863-00	DESOGESTREL-ETHINYL EST	X		
	54868-3948-00	NORETH A-ET ESTRA/FE FU	X		
	54868-3951-00	LEVONORGESTREL-ETH ESTR	X		
	54868-4045-00	NORETHINDRONE-ETHINYL E	X		
	54868-4093-00	NORGESTIMATE-ETHINYL ES	X		
	54868-4100-00	MEDROXYPROGESTERONE ACE	X		
	54868-4100-01	MEDROXYPROGESTERONE ACE	X		
	54868-4196-00	NONOXYNOL 9	X		
	54868-4239-00	LEVONORGESTREL-ETH ESTR	X		
	54868-4240-00	ETHYNODIOL D-ETHINYL ES	X		
	54868-4368-00	LEVONORGESTREL-ETH ESTR	X		
	54868-4369-00	NORETHINDRONE	X		
	54868-4538-00	NORETHINDRONE-ETHINYL E	X		
	54868-4590-00	ETHINYL ESTRADIOL/DROSP	X		
	54868-4607-00	LEVONORGESTREL-ETH ESTR	X		
	54868-4660-00	ESTRAD CYP/M-PROGEST AC	X		
	54868-4670-00	ETHINYL ESTRADIOL/NOREL	X		
	54868-4712-00	NORETHINDRONE	X		
	54868-4730-00	NORGESTIMATE-ETHINYL ES	X		
	54868-4731-00	DESOG-ET ESTRA/ETHIN ES	X		
	54868-4742-00	DESOG-ET ESTRA/ETHIN ES	X		
	54868-4744-00	NORETH A-ET ESTRA/FE FU	X		
	54868-4745-00	NORETH A-ET ESTRA/FE FU	X		
	54868-4754-00	DESOGESTREL-ETHINYL EST	X		
	54868-4776-00	NORETHINDRONE-ETHINYL E	X		
	54868-4778-00	ETHYNODIOL D-ETHINYL ES	X		
	54868-4814-00	NORETHINDRONE	X		
	54868-4828-00	NORGESTIMATE-ETHINYL ES	X		
	54868-4832-00	ETONOGESTREL/ETHINYL ES	X		

54868-4850-00	NORGESTREL-ETHINYL ESTR	X
54868-4851-00	NORGESTREL-ETHINYL ESTR	X
54868-4860-00	LEVONORGESTREL-ETH ESTR	X
54868-4894-00	LEVONORGESTREL	X

State	Code	Description	90% FFP	90% FFP with V25 or FP	HCPCS Required (For HR Codes)
	54868-4911-00	DESOGESTREL-ETHINYL EST	X		
	54868-5028-00	NORGESTIMATE-ETHINYL ES	X		
	54868-5031-00	DESOGESTREL-ETHINYL EST	X		
	54868-5257-00	MEDROXYPROGESTERONE ACE	X		
	54868-5286-00	NORETHINDRONE-ETHINYL E	X		
	54868-5326-00	NORETH A-ET ESTRA/FE FU	X		
	54868-5356-00	LEVONORGESTREL-ETH ESTR	X		
	55045-2839-02	LEVONORGESTREL	X		
	55289-0245-04	NORGESTREL-ETHINYL ESTR	X		
	55289-0246-08	NORGESTREL-ETHINYL ESTR	X		
	55289-0247-08	LEVONORGESTREL-ETH ESTR	X		
	55289-0253-08	LEVONORGESTREL-ETH ESTR	X		
	59762-4537-01	MEDROXYPROGESTERONE ACE	X		
	59762-4537-02	MEDROXYPROGESTERONE ACE	X		
	60346-0159-28	NORETHINDRONE-ETHINYL E	X		
	60346-0448-28	NORETHINDRONE-ETHINYL E	X		
	60346-0601-28	LEVONORGESTREL-ETHIN ES	X		
	60346-0602-28	NORETHINDRONE-ETHIN EST	X		
	63044-0030-12	CONDOMS, LATEX, LUBRICA	X		
	63739-0215-10	PROPOXYPHENE/ACETAMINOPHEN			
	63955-0010-01	L-NORGEST-ETH ESTR/PRG	X		
	64836-0000-01	LEVONORGESTREL	X		
	65152-0100-03	CONDOMS, LATEX, LUBRICA	X		
	65152-0100-12	CONDOMS, LATEX, LUBRICA	X		
	65152-0200-03	CONDOMS, LATEX, LUBRICA	X		
	65152-0200-12	CONDOMS, LATEX, LUBRICA	X		
	65152-0300-12	CONDOMS, LATEX, LUBRICA	X		
	66479-0515-10	PROPOXYPHENE/ACETAMINOPHEN			
	66479-0515-50	PROPOXYPHENE/ACETAMINOPHEN			
	66993-0611-28	DESOGESTREL-ETHINYL EST	X		
	66993-0615-28	DESOGESTREL-ETHINYL EST	X		
	70907-0013-12	CONDOMS, LATEX, LUBRICA	X		
	70907-0140-30	CONDOMS, LATEX, LUBRICA	X		
	70907-0141-20	CONDOMS, LATEX, LUBRICA	X		
	70907-0150-30	CONDOMS, LATEX, LUBRICA	X		
	70907-0151-20	CONDOMS, LATEX, LUBRICA	X		
	70907-0154-60	CONDOMS, LATEX, LUBRICA	X		
	70907-0160-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0161-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0170-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0171-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0174-60	CONDOMS, LATEX, NON-LUB	X		
	70907-0180-30	CONDOMS, LATEX, LUBRICA	X		
	70907-0181-20	CONDOMS, LATEX, LUBRICA	X		
	70907-0184-60	CONDOMS, LATEX, LUBRICA	X		
	70907-0190-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0191-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0201-20	CONDOMS, LATEX, LUBRICA	X		
	70907-0210-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0211-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0240-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0241-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0270-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0271-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0280-30	CONDOMS, LATEX, NON-LUB	X		
	70907-0281-20	CONDOMS, LATEX, NON-LUB	X		
	70907-0291-20	CONDOMS, LATEX, NON-LUB	X		
	72537-0006-00	CONDOMS, LATEX, LUBRICA	X		
	72537-0006-01	CONDOMS, LATEX, LUBRICA	X		
	72537-0039-33	CONDOMS, LATEX, NON-LUB	X		
	72537-0069-31	CONDOMS, LATEX, NON-LUB	X		
	72537-0129-08	CONDOMS, LATEX, LUBRICA	X		
	72537-0129-12	CONDOMS, LATEX, NON-LUB	X		
	72537-0900-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0901-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0903-00	CONDOMS, LATEX, LUBRICA	X		
	72537-0904-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0905-00	CONDOMS, LATEX, LUBRICA	X		
	72537-0911-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0913-00	CONDOMS, LATEX, LUBRICA	X		
	72537-0914-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0921-00	CONDOMS, LATEX, NON-LUB	X		
	72537-0923-00	CONDOMS, LATEX, LUBRICA	X		
	72537-0924-00	CONDOMS, LATEX, NON-LUB	X		

72537-0925-00	CONDOMS, LATEX, NON-LUB	X
72537-0931-00	CONDOMS, LATEX, NON-LUB	X
72537-0945-00	CONDOMS, LATEX, LUBRICA	X
73216-0030-10	CONDOMS, LATEX, LUBRICA	X
73216-0030-40	CONDOMS, LATEX, LUBRICA	X
73216-0030-60	CONDOMS, LATEX, LUBRICA	X
73216-0040-10	CONDOMS, LATEX, LUBRICA	X
73216-0040-20	CONDOMS, LATEX, LUBRICA	X
73216-0050-60	CONDOMS, LATEX, LUBRICA	X
73216-0050-70	CONDOMS, LATEX, NON-LUB	X
73216-0050-80	CONDOMS, LATEX, LUBRICA	X